[go: up one dir, main page]

IN2009CN02662A - - Google Patents

Download PDF

Info

Publication number
IN2009CN02662A
IN2009CN02662A IN2662CHN2009A IN2009CN02662A IN 2009CN02662 A IN2009CN02662 A IN 2009CN02662A IN 2662CHN2009 A IN2662CHN2009 A IN 2662CHN2009A IN 2009CN02662 A IN2009CN02662 A IN 2009CN02662A
Authority
IN
India
Prior art keywords
active substance
buprenorphine
transdermal therapeutic
therapeutic system
administering
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Hille
Michael Horstmann
Walter Muller
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IN2009CN02662A publication Critical patent/IN2009CN02662A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2662CHN2009 2006-11-21 2007-11-07 IN2009CN02662A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054731A DE102006054731B4 (de) 2006-11-21 2006-11-21 Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
PCT/EP2007/009622 WO2008061625A2 (fr) 2006-11-21 2007-11-07 Système thérapeutique transdermique destiné à l'administration de l'agent actif buprénorphine

Publications (1)

Publication Number Publication Date
IN2009CN02662A true IN2009CN02662A (fr) 2015-08-07

Family

ID=39326133

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2662CHN2009 IN2009CN02662A (fr) 2006-11-21 2007-11-07

Country Status (25)

Country Link
US (5) US9308202B2 (fr)
EP (2) EP2094249B1 (fr)
JP (2) JP5763296B2 (fr)
KR (1) KR101444967B1 (fr)
CN (1) CN101528207B (fr)
AR (1) AR064268A1 (fr)
AU (1) AU2007323387B2 (fr)
BR (1) BRPI0719115B8 (fr)
CA (1) CA2670290C (fr)
CY (2) CY1118154T1 (fr)
DE (1) DE102006054731B4 (fr)
DK (2) DK2094249T3 (fr)
ES (2) ES2581574T3 (fr)
HU (2) HUE028971T2 (fr)
IL (2) IL198743A (fr)
IN (1) IN2009CN02662A (fr)
MX (2) MX2009005341A (fr)
NZ (1) NZ575500A (fr)
PL (2) PL2094249T3 (fr)
PT (1) PT2769714E (fr)
RU (1) RU2484822C2 (fr)
SI (2) SI2094249T1 (fr)
TW (1) TWI411452B (fr)
WO (1) WO2008061625A2 (fr)
ZA (1) ZA200901695B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
PT2468274E (pt) * 2010-12-14 2015-09-21 Acino Ag Sistema terapêutico transdérmico para a administração de uma substância ativa
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
EP2729148A4 (fr) 2011-07-06 2015-04-22 Parkinson S Inst Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
CA2858531C (fr) * 2011-12-12 2019-12-17 Lts Lohmann Therapie-Systeme Ag Systeme d'administration transdermique comprenant de la buprenorphine
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9144553B2 (en) * 2012-12-21 2015-09-29 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103893154A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 包含丁丙诺啡的透皮给药系统
EP2938391B1 (fr) 2012-12-28 2022-07-27 Teikoku Seiyaku Co., Ltd. Compositions de buprénorphine à libération transdermique prolongée
JP5768222B2 (ja) * 2013-03-01 2015-08-26 パナソニックＩｐマネジメント株式会社 転写装置および印刷装置
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
LT2810646T (lt) * 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema
WO2014210596A1 (fr) * 2013-06-28 2014-12-31 Purdue Pharma L.P. Traitement d'une arrythmie à l'aide d'un antagoniste des opioïdes
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
EP2921184A1 (fr) 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Pansement de recouvrement à tolérance améliorée et longue durée d'adhérence et son procédé de fabrication
CA2948221C (fr) * 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Systeme d'administration transdermique comprenant un mediateur d'interface
EP3145502B1 (fr) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Système d'administration transdermique contenant de la rotigotine
WO2015177209A1 (fr) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Méthode de régulation de libération d'agent actif dans un système d'administration transdermique
WO2015179782A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinées naturelles et traitement hormonal substitutif
CA2974324A1 (fr) 2015-01-28 2016-08-04 Zita S. Netzel Procedes et systemes d'administration de medicament
BR112017019357A2 (pt) 2015-03-10 2018-06-05 Rhodes Tech sal acetato de buprenorfina e métodos para preparar buprenorfina
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2018526415A (ja) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー 経皮送達システム
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
WO2018129304A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
BR112020003314A2 (pt) * 2017-09-04 2020-08-25 Lts Lohmann Therapie-Systeme Ag sistema de liberação transdérmico incluindo um emulsificante
WO2019064026A1 (fr) 2017-09-29 2019-04-04 Orexo Ab Nouvelles compositions pharmaceutiques
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
BR112020018300A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
AU2019381810B2 (en) 2018-11-16 2025-04-24 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
PL3854388T3 (pl) * 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin
US20230390214A1 (en) * 2020-08-19 2023-12-07 Toyo Ink Sc Holdings Co., Ltd. Adhesive patch

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2002299A1 (fr) * 1988-11-10 1990-05-10 Eugene G. Drust Composes pour l'administration transdermique de sels de buprenorphine
DE3939376C1 (fr) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
CN1195505C (zh) 1999-07-02 2005-04-06 Lts勒曼治疗系统股份公司 以聚硅氧烷及亲两性溶剂为基础的微贮存系统
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (fr) 2001-02-16 2002-10-24 Grünenthal GmbH Utilisation de la buprenorphine pour la production de systemes de delivrance transdermique servant au traitement de l'incontinence urinaire, et specialement de l'incontinence urinaire due a l'urgence urinaire
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050191340A1 (en) 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
EP1526848B1 (fr) * 2002-08-09 2007-07-18 Grünenthal GmbH Antagonistes du recepteur opioide dans des systemes transdermiques a base de buprenorphine
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) * 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
CA2858531C (fr) 2011-12-12 2019-12-17 Lts Lohmann Therapie-Systeme Ag Systeme d'administration transdermique comprenant de la buprenorphine
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema

Also Published As

Publication number Publication date
US20180289698A1 (en) 2018-10-11
CY1118154T1 (el) 2017-06-28
BRPI0719115B1 (pt) 2019-04-24
ES2581574T3 (es) 2016-09-06
PT2769714E (pt) 2015-08-05
WO2008061625A2 (fr) 2008-05-29
EP2769714A1 (fr) 2014-08-27
RU2009123368A (ru) 2010-12-27
HUE026978T2 (en) 2016-08-29
KR101444967B1 (ko) 2014-09-26
TWI411452B (zh) 2013-10-11
DK2094249T3 (en) 2016-08-01
AU2007323387A1 (en) 2008-05-29
CN101528207B (zh) 2012-12-26
DE102006054731A1 (de) 2008-05-29
EP2094249A2 (fr) 2009-09-02
JP5882970B2 (ja) 2016-03-09
PL2094249T3 (pl) 2017-11-30
MX2009005341A (es) 2009-06-01
JP2014028844A (ja) 2014-02-13
US9308202B2 (en) 2016-04-12
JP2010510259A (ja) 2010-04-02
IL198743A (en) 2016-05-31
EP2094249B1 (fr) 2016-04-13
DE102006054731B4 (de) 2013-02-28
MX344241B (es) 2016-12-07
WO2008061625A3 (fr) 2008-09-18
AU2007323387B2 (en) 2014-01-09
CY1117770T1 (el) 2017-05-17
US20160175447A1 (en) 2016-06-23
SI2769714T1 (sl) 2015-09-30
BRPI0719115B8 (pt) 2021-05-25
IL198743A0 (en) 2010-02-17
HK1200373A1 (en) 2015-08-07
ES2543977T3 (es) 2015-08-26
DK2769714T3 (en) 2015-08-03
CA2670290C (fr) 2016-05-31
US20190192506A1 (en) 2019-06-27
HUE028971T2 (en) 2017-01-30
TW200836776A (en) 2008-09-16
RU2484822C2 (ru) 2013-06-20
EP2769714B1 (fr) 2015-05-06
AR064268A1 (es) 2009-03-25
ZA200901695B (en) 2009-12-30
IL245290A0 (en) 2016-06-30
US20100119585A1 (en) 2010-05-13
CN101528207A (zh) 2009-09-09
US20170224676A1 (en) 2017-08-10
KR20090082410A (ko) 2009-07-30
PL2769714T3 (pl) 2015-12-31
SI2094249T1 (sl) 2016-07-29
NZ575500A (en) 2011-12-22
HK1132921A1 (en) 2010-03-12
CA2670290A1 (fr) 2008-05-29
JP5763296B2 (ja) 2015-08-12
BRPI0719115A2 (pt) 2013-12-10

Similar Documents

Publication Publication Date Title
IN2009CN02662A (fr)
NZ807894A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ628092A (en) Transdermal delivery system
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
MX365380B (es) Formulacion de hidrogel que comprende agua con ppotencial de oxidacion-reduccion.
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
WO2009026178A3 (fr) Formulations anesthésiques locales à concentration élevée
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
WO2007095615A3 (fr) Utilisation de derives de benzo-heteroaryl sulfamide dans le traitement de la douleur
SG157402A1 (en) Use of meloxicam in veterinary medicine for the treatment of inflammatory painful diseases
MX2009014102A (es) Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
MX2014002215A (es) Sistema terapeutico transdermico para clorhidrato de acido 5-aminolevulinico.
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
WO2008063563A3 (fr) Méthodes de traitement de maladies liées à l'hyperprolifération de la kératine au moyen d'inhibiteurs de mtor
WO2010065069A3 (fr) Compositions contenant des inhibiteurs du système rénine-angiotensine-aldostérone et des composés de l'acide lipoïque, et leur utilisation pour le traitement des troubles associés au système rénine-angiotensine-aldostérone
CA2863829A1 (fr) Formes galeniques unitaires administrees par voie orale et utilisations de celles-ci pour le traitement de la maladie de gaucher
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
WO2011133479A3 (fr) Polythérapie avec un inhibiteur du protéasome et un complexe de gallium
MD3284G2 (ro) Metodă de tratament al rinitei alergice, dermatitei atopice şi urticariei cronice recidivante
UA94079C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для снятия боли
JO2586B1 (en) Use of different sulfamide derivatives combined with benzo ring for pain management
RU2014126635A (ru) Лечение себореи
MY151422A (en) Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia